http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004042963-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0489 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0497 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0002 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0478 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00 |
| filingDate | 1999-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e66cfd847588d5825298fc15087a229 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df5ef27470b234c9436c2a9da1701e48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_29ddcc6b64436e8f3f00859bd483d9c6 |
| publicationDate | 2004-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2004042963-A1 |
| titleOfInvention | Biomolecule conjugation strategy using novel water-soluble phosphine-based chelating agents |
| abstract | This invention describes a novel strategy to produce phosphine-functionalized biomolecules (e.g. peptides or proteins) for potential use in the design and development of site-specific radiopharmaceuticals for diagnosis or therapy of specific cancers. Hydrophilic alkyl phosphines, in general, tend to be oxidatively unstable. Therefore, incorporation of such phosphine functionalities on peptide (and other biomolecule) backbones, without oxidizing the P III centers, is difficult. In this context this discovery reports on a new technology by which phosphines, in the form of bifunctional chelating agents, can be directly incorporated on biomolecular backbones using manual synthetic or solid phase peptide synthesis methodologies. The superior ligating abilities of phosphine ligands, with various diagnostically (e.g. TC-99m) or therapeutically (e.g. Re186/188, Rh-105, Au-199) useful radiometals, coupled with the findings that the resulting complexes demonstrate high in vivo stability makes this approach useful in the development of radiolabeled biomolecules for applications in the design of tumor-specific radiopharmaceuticals. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008098788-A3 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010111866-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011065680-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2708547-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008098788-A2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2606911-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8961924-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9216228-B2 |
| priorityDate | 1998-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 146.